[go: up one dir, main page]

US20020032217A1 - Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin - Google Patents

Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin Download PDF

Info

Publication number
US20020032217A1
US20020032217A1 US09/446,735 US44673599A US2002032217A1 US 20020032217 A1 US20020032217 A1 US 20020032217A1 US 44673599 A US44673599 A US 44673599A US 2002032217 A1 US2002032217 A1 US 2002032217A1
Authority
US
United States
Prior art keywords
cyclodextrin
cetirizine
active substance
oral administration
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/446,735
Other versions
US6455533B1 (en
Inventor
Domenico Fanara
Monique Berwaer
Philippe Nolf
Henri Vranckx
Michel Deleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3890611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020032217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Assigned to UCB, S.A. reassignment UCB, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERWAER, MONIQUE, DELEERS, MICHEL, FANARA, DOMENICO, NOLF, PHILIPPE, VRANCKX, HENRI
Publication of US20020032217A1 publication Critical patent/US20020032217A1/en
Application granted granted Critical
Publication of US6455533B1 publication Critical patent/US6455533B1/en
Assigned to UCB PHARMA, S.A. reassignment UCB PHARMA, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UCB, S.A.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to pharmaceutical compositions for oral administration, comprising an active substance belonging to the substituted benzhydrylpiperazine family and a cyclodextrin.
  • R and R 1 represent, independently of each other, a hydrogen or halogen atom, or an alkyl or alkoxy group, where R and R 1 can be in an ortho, meta or para position, and n represents the number 1 or 2, as well as the pharmaceutically acceptable salts thereof.
  • Patent EP 58146 in the name of the Applicant describes substituted benzhydrylpiperazines corresponding to the general formula
  • L represents an —OH or —NH 2 group
  • X and X′ taken individually, represent a hydrogen atom, a halogen atom, a linear or branched C 1 or C 4 alkoxy radical or a trifluoromethyl radical
  • m is equal to 1 or 2
  • n is equal to 1 or 2, as well as the pharmaceutically acceptable salts thereof.
  • U.S. Pat. No. 3,558,600 describes a method for masking the bitter taste of antihistaminic agents belonging to the substituted 1-(p-chlorobenzhydryl)piperazine family, which consists in converting the active substance in free base form into the form of its salt with a long-chain alkyl sulfate, for example such as stearyl sulfate.
  • Another known method for masking the taste of active principles consists in forming an inclusion complex between the active principle and a cyclodextrin.
  • the masking of the taste arises from the trapping of the active principle which cannot be released as it passes through the mouth.
  • this solution to the problem of masking the taste entails another problem specific to the masking of the taste of orally administered pharmaceutically active substances, namely the problem of the bioavailability and speed of action of the active principle.
  • the association constant of the inclusion complex is too large, there is a risk that the active principle will not be released easily enough to allow good absorption in the gastrointestinal tract. In this case, the expected therapeutic effect cannot be obtained.
  • Patent EP 399,902 mentions this twofold problem intrinsic to pharmaceutical compositions for oral administration, namely the masking of taste combined with good bioavailability. That patent describes freeze-dried and porous pharmaceutical forms comprising, besides the conventional excipients and additives for this type of formulation, the active principle and a cyclodextrin, as well as processes for preparing these pharmaceutical forms.
  • Pharmaceutical compositions containing the following active principles are described in the embodiment examples of the invention: ketoprofen, trimipramine methanesulfonate, zopiclone, phenobarbital, vitamin A, lemon essence, pritinamycin or vitamin D 3 .
  • the Applicant thus set itself the aim of searching for novel pharmaceutical compositions which allow easier oral administration of pharmaceutical substances belonging to the substituted benzhydrylpiperazine family than is possible with the current compositions, while still ensuring good bioavailability of the active substance.
  • the present invention relates to pharmaceutical compositions for oral administration comprising an active substance belonging to the substituted benzhydrylpiperazine family and at least one cyclodextrin.
  • the cyclodextrins which can be used according to the present invention can be chosen from ⁇ , ⁇ or ⁇ cyclodextrins, or from alkyl or hydroxyalkyl derivatives thereof, such as heptakis(2,6-di-o-methyl)- ⁇ -cyclodextrin (commonly abbreviated to DIMEB), randomly methylated ⁇ -cyclodextrin (commonly abbreviated to RAMEB) and hydroxypropyl ⁇ -cyclodextrin (commonly abbreviated to HP ⁇ CD).
  • DIMEB heptakis(2,6-di-o-methyl)- ⁇ -cyclodextrin
  • RAMEB randomly methylated ⁇ -cyclodextrin
  • HP ⁇ CD hydroxypropyl ⁇ -cyclodextrin
  • compositions according to the present invention can be in various orally-administrable forms.
  • the pharmaceutical compositions according to the present invention can be in the form of dry syrups, chewable tablets, granules or sublingual tablets which are particularly suitable for oral administration without simultaneous absorption of liquid.
  • excipients used are the conventional excipients used for compositions of this type.
  • diluents such as polyols (mannitol, sorbitol, sucrose, etc.) and flavorings can be used, for example.
  • any conventional excipient which gives good tabletting parameters can be used, such as diluents (mannitol, sorbitol, etc.), crumbling agents or swelling agents (polyvinylpolypyrrolidone, sodium croscarmellose, starches and derivatives, cellulose and derivatives, etc.), lubricants (magnesium stearate, etc.), flow agents (Aerosil 200, etc.) and flavorings.
  • compositions of this type any common method used by pharmacists for the preparation of compositions of this type can be used.
  • the complex of the active substance with cyclodextrin can be prepared beforehand, for example by blending the active substance and the cyclodextrin in the presence of water or by preparing an aqueous solution containing the active substance and the cyclodextrin in the desired molar ratio.
  • the active substance and the cyclodextrin can be simply mixed together with the other excipients and adjuvants.
  • ⁇ -cyclodextrin a solution of 2 mg/ml of cetirizine dihydrochloride such that the molar ratio between the ⁇ -cyclodextrin and the cetirizine is respectively 0, 0.5, 1.0, 2.0 and 4.0.
  • cetirizine dihydrochloride is very soluble in water at neutral pH, its solubility is much lower when the pH is between 2.5 and 3.5 (solubility of about 1 g/100 ml).
  • the modification of the solubility of cetirizine dihydrochloride in water at pH 3.4 in the presence of ⁇ -cyclodextrin was examined, in order to demonstrate the formation of an inclusion complex between cetirizine and ⁇ -cyclodextrin.
  • Solution A contained cetirizine dihydrochloride in water at pH 3.4
  • solution B contained cetirizine dihydrochloride and ⁇ -cyclodextrin in a 1:1 molar ratio in water at pH 3.4. These two solutions were stirred at room temperature until thermodynamic equilibrium was reached.
  • ⁇ -cyclodextrin is sparingly soluble in water (1.85 g/100 ml). Its solubility increases gradually as cetirizine dihydrochloride is added, up to a 1:1 ⁇ -cyclodextrin/cetirizine molar ratio. At pH 3.4, the solubility of ⁇ -cyclodextrin increases by a factor of at least 30.
  • Nuclear magnetic resonance (NMR) spectroscopy is commonly used to demonstrate the formation of inclusion complexes with cyclodextrins (F. Djedaini and B. Perly in D. Duchene, New Trends in Cyclodextrin and Derivatives, Chap. 6, ⁇ 2&3, Edition de Santé, Paris 1991, F. Djedaini et al., J. Pharm. Sciences, 79 (7), 643-646 (1990)).
  • the stoichiometric coefficient for the complex was determined by the technique of continuous variation, also known as the “Job method” (see F. Djedaini et al., J. Pharm. Sciences, 79 (7), 643-646 (1990), P. Job, Ann. Chim., 9, 113-134 (1928)). Variation of the chemical shift for proton 3 of ⁇ -cyclodextrin was taken as variable. By this method, it is determined that the complex formed has a 1:1 stoichiometry.
  • Cetirizine dihydrochloride (10 parts) and ⁇ -cyclodextrin (55 parts) are blended in the presence of water in a planetary mixer for 20 minutes. In this way, the complex between the cetirizine dihydrochloride and the ⁇ -cyclodextrin is formed. This mixture is then dried in an oven.
  • the complex is mixed with the following excipients: Sorbitol (29.45 parts), Acesulfam K (0.7 parts) Aerosil 200 (0.3 parts), Croscarmellose sodium (2.1 parts), Glycamil (1.2 part), liquorice flavoring (0.25 part).
  • the mixture is then tabletted in a conventional manner.
  • the cetirizine dihydrochloride and ⁇ -cyclodextrin complex is prepared in the same way as in Example 6.
  • the excipients used are as follows: Polyvinylpolypyrrolidone (35 parts), Avicel pH 101 (50 part), Avicel CE 15 (7 parts), Aerosil 200 (1 part), magnesium stearate (1.6 parts), Acesulfam K (1.4 part), flavorings (2.7 parts).
  • compositions A and B were prepared by mixing together the ingredients given in the table: Constituent (in parts) A B Cetirizine dihydrochioride 5 10 ⁇ -cyclodextrin 27.5 55 Flavoring 0.5 0.5 Mannitol qs 1000 qs 1000
  • the mixture is granulated with water in a planetary mixer and then extruded.
  • the extrudate obtained is dried on a fluidized-air bed.
  • composition C was prepared by mixing together the ingredients given in the table: Constituent (in parts) C Hydroxyzine dihydrochioride 25 ⁇ -cyclodextrin 142 Flavoring 2 Impalpable sucrose qs 1000
  • the mixture is granulated with water in a planetary mixer and then extruded.
  • the extrudate is dried in a fluidized-air bed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.

Description

  • The present invention relates to pharmaceutical compositions for oral administration, comprising an active substance belonging to the substituted benzhydrylpiperazine family and a cyclodextrin. [0001]
  • Many substances belonging to the substituted benzhydrylpiperazine family are known as being substances which have advantageous pharmacological properties. [0002]
  • For example, GB patent 817,231 in the name of the Applicant describes substituted benzhydrylpiperazines corresponding to the general formula [0003]
    Figure US20020032217A1-20020314-C00001
  • in which R and R[0004] 1 represent, independently of each other, a hydrogen or halogen atom, or an alkyl or alkoxy group, where R and R1 can be in an ortho, meta or para position, and n represents the number 1 or 2, as well as the pharmaceutically acceptable salts thereof.
  • Among these compounds is found, in particular, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-ethoxy]ethanol, also known as hydroxyzine, and the dihydrochloride thereof, which are well known for their antihistaminic and tranquilizing properties. [0005]
  • Patent EP 58146 in the name of the Applicant describes substituted benzhydrylpiperazines corresponding to the general formula [0006]
    Figure US20020032217A1-20020314-C00002
  • in which L represents an —OH or —NH[0007] 2 group, X and X′, taken individually, represent a hydrogen atom, a halogen atom, a linear or branched C1 or C4 alkoxy radical or a trifluoromethyl radical, m is equal to 1 or 2 and n is equal to 1 or 2, as well as the pharmaceutically acceptable salts thereof.
  • Among these compounds, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]acetic acid, also known as cetirizine and the dihydrochloride thereof are well known for their antihistaminic properties. [0008]
  • Hitherto, the only commercial pharmaceutical compositions for oral administration containing compounds of this type are of conventional type. In the case of film-coated tablets, administration takes place by swallowing by means of the simultaneous absorption of liquid. When the absorption needs to take place without simultaneous absorption of liquid (pre- or postoperative conditions, absence of drinking water, etc.), a conventional mode of administration is unsuitable on account of the extremely bitter taste of these substituted benzhydrylpiperazines. [0009]
  • Various techniques intended to mask the taste of pharmaceutical substances have been described. [0010]
  • For example, U.S. Pat. No. 3,558,600 describes a method for masking the bitter taste of antihistaminic agents belonging to the substituted 1-(p-chlorobenzhydryl)piperazine family, which consists in converting the active substance in free base form into the form of its salt with a long-chain alkyl sulfate, for example such as stearyl sulfate. [0011]
  • Another known method for masking the taste of active principles consists in forming an inclusion complex between the active principle and a cyclodextrin. In this case, the masking of the taste arises from the trapping of the active principle which cannot be released as it passes through the mouth. However, this solution to the problem of masking the taste entails another problem specific to the masking of the taste of orally administered pharmaceutically active substances, namely the problem of the bioavailability and speed of action of the active principle. Specifically, if the association constant of the inclusion complex is too large, there is a risk that the active principle will not be released easily enough to allow good absorption in the gastrointestinal tract. In this case, the expected therapeutic effect cannot be obtained. [0012]
  • Patent EP 399,902 mentions this twofold problem intrinsic to pharmaceutical compositions for oral administration, namely the masking of taste combined with good bioavailability. That patent describes freeze-dried and porous pharmaceutical forms comprising, besides the conventional excipients and additives for this type of formulation, the active principle and a cyclodextrin, as well as processes for preparing these pharmaceutical forms. Pharmaceutical compositions containing the following active principles are described in the embodiment examples of the invention: ketoprofen, trimipramine methanesulfonate, zopiclone, phenobarbital, vitamin A, lemon essence, pritinamycin or vitamin D[0013] 3.
  • However, that document does not make it possible to conclude that the masking of taste and the bioavailability of these active principles are indeed obtained in all cases. In the case of pharmaceutical substances belonging to the substituted benzhydrylpiperazine family, this problem is of special importance since, although it is desirable to mask the extremely bitter, unpleasant taste of these active principles, it is also essential that they should be released immediately after administration in order to obtain a rapid and efficient effect. [0014]
  • The Applicant thus set itself the aim of searching for novel pharmaceutical compositions which allow easier oral administration of pharmaceutical substances belonging to the substituted benzhydrylpiperazine family than is possible with the current compositions, while still ensuring good bioavailability of the active substance. [0015]
  • We have just discovered novel pharmaceutical forms for oral administration which make it possible both to efficiently mask the taste of substances belonging to the substituted benzhydrylpiperazine family and to obtain good bioavailability of these compounds when they are administered orally, even without liquid being taken simultaneously. In particular, the Applicant set itself the aim of searching for such formulations which are in the form of chewable tablets, dry syrups, granules or sublingual tablets. [0016]
  • Accordingly, the present invention relates to pharmaceutical compositions for oral administration comprising an active substance belonging to the substituted benzhydrylpiperazine family and at least one cyclodextrin. [0017]
  • The cyclodextrins which can be used according to the present invention can be chosen from α, β or γ cyclodextrins, or from alkyl or hydroxyalkyl derivatives thereof, such as heptakis(2,6-di-o-methyl)-β-cyclodextrin (commonly abbreviated to DIMEB), randomly methylated β-cyclodextrin (commonly abbreviated to RAMEB) and hydroxypropyl β-cyclodextrin (commonly abbreviated to HPβCD). [0018]
  • Among the active substances belonging to the substituted benzhydrylpiperazine family which will be mentioned in particular are 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid (cetirizine), 2-[2-[4-[(4-chlorophenyl)phenyl-methyl]-1-piperazinyl]ethoxy]ethanol (hydroxyzine), 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-ethoxy]acetic acid (efletirizine), 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine (meclizine) or 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)phenylmethyl]piperazine (buclizine), the optically active isomers thereof and the pharmaceutically acceptable salts thereof. [0019]
  • The pharmaceutical compositions according to the present invention can be in various orally-administrable forms. In particular, the pharmaceutical compositions according to the present invention can be in the form of dry syrups, chewable tablets, granules or sublingual tablets which are particularly suitable for oral administration without simultaneous absorption of liquid. [0020]
  • The excipients used are the conventional excipients used for compositions of this type. [0021]
  • In the case of dry syrups and granules, diluents such as polyols (mannitol, sorbitol, sucrose, etc.) and flavorings can be used, for example. [0022]
  • In the case of chewable tablets, any conventional excipient which gives good tabletting parameters can be used, such as diluents (mannitol, sorbitol, etc.), crumbling agents or swelling agents (polyvinylpolypyrrolidone, sodium croscarmellose, starches and derivatives, cellulose and derivatives, etc.), lubricants (magnesium stearate, etc.), flow agents (Aerosil 200, etc.) and flavorings. [0023]
  • In the case of sublingual tablets, the excipients cited above can be used, selecting those which are water-soluble. [0024]
  • As regards the preparation methods, any common method used by pharmacists for the preparation of compositions of this type can be used. [0025]
  • If so desired, the complex of the active substance with cyclodextrin can be prepared beforehand, for example by blending the active substance and the cyclodextrin in the presence of water or by preparing an aqueous solution containing the active substance and the cyclodextrin in the desired molar ratio. [0026]
  • Alternatively, the active substance and the cyclodextrin can be simply mixed together with the other excipients and adjuvants.[0027]
  • The examples which follow illustrate the present invention without limiting it. In these examples, the parts are expressed on a weight basis. [0028]
    • EXAMPLE 1
  • Bitterness test [0029]
  • Various solutions are prepared by adding β-cyclodextrin to a solution of 2 mg/ml of cetirizine dihydrochloride such that the molar ratio between the β-cyclodextrin and the cetirizine is respectively 0, 0.5, 1.0, 2.0 and 4.0. [0030]
  • The bitterness of these solutions was tested on a group of 7 individuals. The results of this test are given in Table 1. [0031]
    TABLE 1
    Bitterness test
    Molar ratio
    β-CD/cetirizine 0.0 0.5 1.0 2.0 4.0
    Absence of bitterness 0 0 0 3 7
    Very faintly bitter 0 1 6 4 0
    Strongly bitter 7 6 1 0 0
  • A reduction in the bitterness of cetirizine dihydrochloride is noted when β-cyclodextrin is added to the cetirizine dihydrochloride solution. This reduction is particularly noticeable when the molar ratio between the β-cyclodextrin and the cetirizine dihydrochloride is between 1.0 and 4.0. [0032]
    • EXAMPLE 2
  • Solubility test [0033]
  • The solubility of hydrophobic molecules in water is increased in the presence of cyclodextrins, as regards both the rate of dissolution and the amount of active substance dissolved. Modification of the solubility in water of a hydrophobic active substance in the presence of cyclodextrin thus constitutes a method commonly used for demonstrating the formation of an inclusion complex (see J. Szetli, in V. F. Smolen and L. A. Ball, Controlled Drug Bioavailability, Vol. 3, Wiley, New York (1985), 365-420). [0034]
  • Although cetirizine dihydrochloride is very soluble in water at neutral pH, its solubility is much lower when the pH is between 2.5 and 3.5 (solubility of about 1 g/100 ml). In this test, the modification of the solubility of cetirizine dihydrochloride in water at pH 3.4 in the presence of β-cyclodextrin was examined, in order to demonstrate the formation of an inclusion complex between cetirizine and β-cyclodextrin. [0035]
  • Two solutions A and B were prepared. Solution A contained cetirizine dihydrochloride in water at pH 3.4; solution B contained cetirizine dihydrochloride and β-cyclodextrin in a 1:1 molar ratio in water at pH 3.4. These two solutions were stirred at room temperature until thermodynamic equilibrium was reached. [0036]
  • After stirring, only a very small amount of cetirizine (1 g/100 ml of water) could be dissolved in solution A. On the other hand, solution B allowed 27 g/100 ml of cetirizine to be dissolved in the aqueous phase. [0037]
  • Moreover, β-cyclodextrin is sparingly soluble in water (1.85 g/100 ml). Its solubility increases gradually as cetirizine dihydrochloride is added, up to a 1:1 β-cyclodextrin/cetirizine molar ratio. At pH 3.4, the solubility of β-cyclodextrin increases by a factor of at least 30. [0038]
  • EXAMPLE 3 [0039]
  • Demonstration of the formation of a complex by UV spectroscopy. [0040]
  • The complexation of a host with a cyclodextrin is generally reflected by a slight displacement of the absorption maximum in UV spectroscopy and/or by a change in the molar extinction coefficient (J. Szetli in Cyclodextrin Technology, Chapter 2.2.4.2, Kluwer Academic Publishers, 1988). [0041]
  • Various solutions containing various molar ratios of cetirizine dihydrochloride/p-cyclodextrin were prepared and the differences in absorbence at 230 nm were determined. The reason for this is that, in water, cetirizine has an absorption maximum at 230 nm in the absence of cyclodextrin. [0042]
  • A decrease in the absorbence at the absorption maximum gradually as the β-cyclodextrin concentration increases is observed. This hypochromatic effect indicates the formation of an inclusion complex. [0043]
    • EXAMPLE 4
  • Competition for the complexation with colored indicators [0044]
  • In this example, changes in the absorption spectrum in the visible range of a solution containing a complex between a cyclodextrin and a colored indicator when cetirizine is introduced into the solution are observed. In this case, the cetirizine comes into competition with the colored indicator for the formation of an inclusion complex. The changes in the visible-range spectrum thus make it possible to determine whether or not cetirizine forms an inclusion complex with cyclodextrin. [0045]
  • Two acid-base indicators were used; crystal violet and methyl orange. In the case of the acid-base indicators, the changes in the absorption spectrum due to complexation with a cyclodextrin are often large given that the complexation brings about a change in the pK of the indicator. If the pH of the solution is close to the pK, the addition of a cyclodextrin to an acid-base indicator solution brings about ionization or deionization of the indicator, which is reflected by a change in the color of the solution. Consequently, the absorption maximum in the visible spectrum is displaced as a function of the degree of complexation. [0046]
  • When cetirizine dihydrochloride is introduced into an aqueous solution containing an acid-base indicator and β-cyclodextrin, a displacement of the absorption maximum is also observed, indicating thereby that some of the indicator is no longer complexed with the β-cyclodextrin. This means that some of the β-cyclodextrin has been used to complex the cetirizine introduced into the medium. (J. Szetli in Cyclodextrin Technology, Chapter 2.2.4.1, Kluwer Academic Publishers, 1988). [0047]
  • An average value for the association constant of 3292 mol[0048] −1 for the competition with crystal violet, and of 3587 mol−1 for the competition with methyl orange, are determined.
    • EXAMPLE 5
  • Identification of the formation of a complex by proton NMR. [0049]
  • Nuclear magnetic resonance (NMR) spectroscopy is commonly used to demonstrate the formation of inclusion complexes with cyclodextrins (F. Djedaini and B. Perly in D. Duchene, New Trends in Cyclodextrin and Derivatives, Chap. 6, § 2&3, Edition de Santé, Paris 1991, F. Djedaini et al., J. Pharm. Sciences, 79 (7), 643-646 (1990)). [0050]
  • In this test, various solutions containing variable molar ratios of β-cyclodextrin/cetirizine dihydrochloride in a 9:1 H[0051] 2O/D2O mixture were analyzed by proton NMR spectroscopy. The observed regions of the spectrum correspond to the resonant frequency zone for protons 2 to 6.6′ (d=3.0 to 4.0 ppm) of β-cyclodextrin and to the resonant frequency zone of the aromatic protons of cetirizine (d=7.2 to 7.6 ppm).
  • Only one resonance peak at an average resonant frequency between the resonant frequency of the free molecule and that of the complexed molecule is observed for each proton. This means that the system analyzed is in an exchange regime which is faster than the time scale of the NMR measurement. [0052]
  • When the amount of cetirizine present in solution with the β-cyclodextrin increases, a large shift upfield is observed for the protons located inside the hydrophobic cavity of β-cyclodextrin (protons 3 and 5). On the other hand, the resonant frequencies of the protons located on the outside of the β-cyclodextrin cavity (protons 2 and 4) hardly shift at all. This clearly demonstrates the formation of an inclusion complex in the β-cyclodextrin cavity. [0053]
  • As regards the protons of cetirizine, it is found that only the aromatic protons undergo a shift in their resonant frequency. The full interpretation is complicated by the overlapping of the resonance signals of the 9 aromatic protons. This observation indicates the inclusion of the aromatic portion of cetirizine in the β-cyclodextrin cavity. [0054]
  • In addition, the stoichiometric coefficient for the complex was determined by the technique of continuous variation, also known as the “Job method” (see F. Djedaini et al., J. Pharm. Sciences, 79 (7), 643-646 (1990), P. Job, Ann. Chim., 9, 113-134 (1928)). Variation of the chemical shift for proton 3 of β-cyclodextrin was taken as variable. By this method, it is determined that the complex formed has a 1:1 stoichiometry. [0055]
    • EXAMPLE 6
  • Chewable polyol-based cetirizine tablets [0056]
  • Cetirizine dihydrochloride (10 parts) and β-cyclodextrin (55 parts) are blended in the presence of water in a planetary mixer for 20 minutes. In this way, the complex between the cetirizine dihydrochloride and the β-cyclodextrin is formed. This mixture is then dried in an oven. [0057]
  • After drying, the complex is mixed with the following excipients: Sorbitol (29.45 parts), Acesulfam K (0.7 parts) Aerosil 200 (0.3 parts), Croscarmellose sodium (2.1 parts), Glycamil (1.2 part), liquorice flavoring (0.25 part). [0058]
  • The mixture is then tabletted in a conventional manner. [0059]
    • EXAMPLE 7
  • Polyol-free chewable cetirizine tablets [0060]
  • The cetirizine dihydrochloride and β-cyclodextrin complex is prepared in the same way as in Example 6. The excipients used are as follows: Polyvinylpolypyrrolidone (35 parts), Avicel pH 101 (50 part), Avicel CE 15 (7 parts), Aerosil 200 (1 part), magnesium stearate (1.6 parts), Acesulfam K (1.4 part), flavorings (2.7 parts). [0061]
    • EXAMPLE 8
  • Dry cetirizine syrup [0062]
  • Two compositions A and B were prepared by mixing together the ingredients given in the table: [0063]
    Constituent (in parts) A B
    Cetirizine dihydrochioride 5 10
    β-cyclodextrin 27.5 55
    Flavoring 0.5 0.5
    Mannitol qs 1000 qs 1000
  • The mixture is granulated with water in a planetary mixer and then extruded. The extrudate obtained is dried on a fluidized-air bed. [0064]
    • EXAMPLE 9
  • Hydroxyzine granules [0065]
  • A composition C was prepared by mixing together the ingredients given in the table: [0066]
    Constituent (in parts) C
    Hydroxyzine dihydrochioride  25
    β-cyclodextrin 142
    Flavoring  2
    Impalpable sucrose qs 1000
  • The mixture is granulated with water in a planetary mixer and then extruded. The extrudate is dried in a fluidized-air bed. [0067]

Claims (5)

1. Pharmaceutical compositions for oral administration comprising an active substance belonging to the substituted benzhydrylpiperazine family and at least one cyclodextrin.
2. Pharmaceutical composition according to claim 1, characterized in that it is in the form of a chewable tablet, a dry syrup, granules or a sublingual tablet.
3. Pharmaceutical composition according to claim 1 or 2, characterized in that the active substance is chosen from the group consisting of cetirizine, hydroxyzine, efletirizine, meclizine and buclizine, the optically active isomers thereof and the pharmaceutically acceptable salts thereof.
4. Pharmaceutical composition according to any one of claims 1 to 3, characterized in that the cyclodextrin is chosen from the group consisting of α, β or γ cyclodextrins and alkyl or hydroxyalkyl derivatives thereof, such as heptakis(2,6-di-o-methyl)-β-cyclodextrin, randomly methylated β-cyclodextrin and hydroxypropyl β-cyclodextrin.
5. Pharmaceutical composition according to any one of claims 1 to 4, characterized in that the molar ratio between the cyclodextrin and the active substance is between 1.0 and 4.0.
US09/446,735 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin Expired - Lifetime US6455533B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9700572A BE1011251A3 (en) 1997-07-03 1997-07-03 Pharmaceutical administrable oral, including an active substance and cyclodextrin.
BE9700572 1997-07-03
PCT/BE1998/000100 WO1999001133A1 (en) 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin

Publications (2)

Publication Number Publication Date
US20020032217A1 true US20020032217A1 (en) 2002-03-14
US6455533B1 US6455533B1 (en) 2002-09-24

Family

ID=3890611

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/446,735 Expired - Lifetime US6455533B1 (en) 1997-07-03 1998-07-02 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin

Country Status (20)

Country Link
US (1) US6455533B1 (en)
EP (1) EP0994710B2 (en)
JP (2) JP2002508773A (en)
KR (1) KR100551510B1 (en)
CN (1) CN1150900C (en)
AT (1) ATE224717T1 (en)
AU (1) AU727140B2 (en)
BE (1) BE1011251A3 (en)
BR (1) BR9810495A (en)
CA (1) CA2294783C (en)
DE (1) DE69808297T3 (en)
DK (1) DK0994710T4 (en)
ES (1) ES2184293T5 (en)
ID (1) ID23806A (en)
IL (1) IL133397A (en)
NZ (1) NZ501820A (en)
PL (1) PL192348B1 (en)
PT (1) PT994710E (en)
RU (1) RU2192863C2 (en)
WO (1) WO1999001133A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084511A1 (en) * 2002-04-04 2003-10-16 Pfizer Products Inc. Palatable chewable tablet
US20040213839A1 (en) * 2001-02-05 2004-10-28 Andrew Favara Methods and compositions for reducing the taste of pharmaceutically active agents
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
US20090111833A1 (en) * 2007-10-31 2009-04-30 Long Walker Anderson Injectable meclizine formulations and methods
US20100189768A1 (en) * 2007-07-11 2010-07-29 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
US20100260818A1 (en) * 2007-07-11 2010-10-14 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
US20120010218A1 (en) * 2002-01-15 2012-01-12 Domenico Fanara Formulations
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
WO2011110939A3 (en) * 2010-03-11 2012-04-26 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
WO2015144830A1 (en) * 2014-03-27 2015-10-01 Ucb Farchim S.A. Pharmaceutical compositions comprising levocetirizine
KR20190003323A (en) * 2017-06-30 2019-01-09 한미약품 주식회사 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US12083112B2 (en) 2015-03-04 2024-09-10 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US12508313B2 (en) 2009-08-19 2025-12-30 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
JP2008143807A (en) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd Capsule of drug for common cold and method for producing the same
WO2009054432A1 (en) * 2007-10-26 2009-04-30 Daiichi Sankyo Company, Limited Intraorally rapidly disintegrating pharmaceutical composition, and method for production thereof
WO2009061465A1 (en) * 2007-11-06 2009-05-14 Teva Pharmaceutical Industries Ltd. Chewable formulations
AU2009288006B2 (en) * 2008-09-05 2014-07-17 Mcneil-Ppc, Inc. Method for making cetirizine tablets
CN101905027A (en) * 2010-07-27 2010-12-08 北京华禧联合科技发展有限公司 Oral pharmaceutical composition containing mitiglinide calcium and cyclodextrin
RU2589833C2 (en) * 2013-12-12 2016-07-10 Общество С Ограниченной Ответственностью "Фарма Старт" Solid dosage form of preparation of sedative and hypnotic effect
KR20220137065A (en) * 2020-02-03 2022-10-11 존슨 앤드 존슨 컨수머 인코포레이티드 Single-Layer Chewable Tablets Containing Cetirizine
JP2023549381A (en) 2020-11-18 2023-11-24 バイオファーマ・シナジーズ，エス．エル． Orodispersible powder compositions containing antihistamine active compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (en) * 1981-02-06 1987-06-10 Ucb Sa ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS.
JPS58177949A (en) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd Clathrate compound of lankacidin-group antibiotic substance
JPS60204712A (en) * 1984-03-29 1985-10-16 Ss Pharmaceut Co Ltd Stabilized liquid composition of meclizine hydrochloride
JPS63243031A (en) † 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd Solid pharmaceutical of bile acid
FR2647343B1 (en) * 1989-05-24 1994-05-06 Rhone Poulenc Sante NOVEL POROUS PHARMACEUTICAL FORM AND ITS PREPARATION
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
JPH08501561A (en) † 1992-09-24 1996-02-20 セプラコア，インコーポレイテッド (-) Composition for treating allergic diseases using cetirizine
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
AU683964B2 (en) * 1993-12-01 1997-11-27 Altana Pharma Ag Substituted aminoalkylaminopyridines
US5866179A (en) 1996-05-03 1999-02-02 Avant-Garde Technologies & Products S.A. Medicated chewing gum and a process for preparation thereof
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
EP1771161B1 (en) * 2004-07-22 2010-04-21 Bend Research, Inc Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213839A1 (en) * 2001-02-05 2004-10-28 Andrew Favara Methods and compositions for reducing the taste of pharmaceutically active agents
US20120010218A1 (en) * 2002-01-15 2012-01-12 Domenico Fanara Formulations
US20030215503A1 (en) * 2002-04-04 2003-11-20 Tanya Havlir Palatable chewable tablet
WO2003084511A1 (en) * 2002-04-04 2003-10-16 Pfizer Products Inc. Palatable chewable tablet
US7482022B2 (en) 2002-04-04 2009-01-27 Pfizer Inc. Palatable chewable tablet
WO2006011051A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20080075784A1 (en) * 2004-07-22 2008-03-27 Pfizer Inc. Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
US20100189768A1 (en) * 2007-07-11 2010-07-29 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
US20100260818A1 (en) * 2007-07-11 2010-10-14 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009059120A3 (en) * 2007-10-31 2009-08-06 Genebiology Inc Injectable meclizine formulations and methods
US20090111833A1 (en) * 2007-10-31 2009-04-30 Long Walker Anderson Injectable meclizine formulations and methods
US8138192B2 (en) 2007-10-31 2012-03-20 Genebiology, Inc. Injectable meclizine formulations and methods
US12508313B2 (en) 2009-08-19 2025-12-30 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011110939A3 (en) * 2010-03-11 2012-04-26 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
EP3210597A1 (en) 2010-09-13 2017-08-30 Bev-RX, Inc. Aqueous drug delivery system comprising off- flavor masking agent
US9789191B2 (en) 2010-09-13 2017-10-17 Solixa Technologies, Inc. Aqueous drug delivery system
WO2012037117A1 (en) 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
US9018193B2 (en) 2010-09-13 2015-04-28 Bev-Rx, Inc. Aqueous drug delivery system
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EA036278B1 (en) * 2014-03-27 2020-10-21 Юсб Фархим С.А. Pharmaceutical composition
WO2015144830A1 (en) * 2014-03-27 2015-10-01 Ucb Farchim S.A. Pharmaceutical compositions comprising levocetirizine
US10822307B2 (en) 2014-08-28 2020-11-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11186547B2 (en) 2014-08-28 2021-11-30 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US12083112B2 (en) 2015-03-04 2024-09-10 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR102110304B1 (en) * 2017-06-30 2020-05-14 한미약품 주식회사 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof
KR20190003323A (en) * 2017-06-30 2019-01-09 한미약품 주식회사 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof

Also Published As

Publication number Publication date
ATE224717T1 (en) 2002-10-15
EP0994710A1 (en) 2000-04-26
KR100551510B1 (en) 2006-02-13
AU8201598A (en) 1999-01-25
CN1261799A (en) 2000-08-02
US6455533B1 (en) 2002-09-24
DE69808297D1 (en) 2002-10-31
BR9810495A (en) 2000-09-12
ES2184293T5 (en) 2006-01-16
ES2184293T3 (en) 2003-04-01
DE69808297T2 (en) 2003-04-17
IL133397A (en) 2005-07-25
PL192348B1 (en) 2006-10-31
PT994710E (en) 2003-02-28
WO1999001133A1 (en) 1999-01-14
ID23806A (en) 2000-05-11
AU727140B2 (en) 2000-12-07
EP0994710B1 (en) 2002-09-25
IL133397A0 (en) 2001-04-30
PL337794A1 (en) 2000-09-11
NZ501820A (en) 2000-10-27
DE69808297T3 (en) 2006-01-19
CN1150900C (en) 2004-05-26
JP2007091760A (en) 2007-04-12
BE1011251A3 (en) 1999-06-01
EP0994710B2 (en) 2005-09-21
HK1029060A1 (en) 2001-03-23
KR20010014398A (en) 2001-02-26
CA2294783C (en) 2006-11-14
JP2002508773A (en) 2002-03-19
DK0994710T3 (en) 2003-01-20
CA2294783A1 (en) 1999-01-14
RU2192863C2 (en) 2002-11-20
DK0994710T4 (en) 2005-10-17

Similar Documents

Publication Publication Date Title
US6455533B1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
US8999952B2 (en) Aripiprazole complex formulation and method
AP796A (en) Inclusion complexes of aryl-heterocyclic salts.
JP2002503267A (en) Solid preparations containing a physical mixture of a sulfoalkyl ether cyclodextrin and a therapeutic agent
EP2022497B1 (en) Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof
US6077871A (en) Droloxifene pharmaceutical compositions
Chowdary et al. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with β-cyclodextrin
Becirevic Brussels (BE); Michel Deleers, Linkebeek (BE) FOREIGN PATENT DOCUMENTS
MXPA99011899A (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
HK1029060B (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Rane et al. Development and evaluation of taste maske d formulations of fexofenadine hydrochloride
Anghore Design and Evaluation of Ketoprofen Matrix Tablet by Using β-Cyclodextrin Complexes
CZ145696A3 (en) Estramustine formulations exhibiting improved pharmaceutical properties
WO2024217724A1 (en) Pharmaceutical composition comprising an antimicrobial agent and method for the preparation thereof
CN116173236A (en) Halofuginone sulfobutyl ether cyclodextrin inclusion compound and preparation method thereof
RU2237478C2 (en) Antimicrobial pharmaceutical composition
MXPA98009888A (en) Pharmaceutical compositions of droloxif

Legal Events

Date Code Title Description
AS Assignment

Owner name: UCB, S.A., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FANARA, DOMENICO;BERWAER, MONIQUE;NOLF, PHILIPPE;AND OTHERS;REEL/FRAME:010594/0476

Effective date: 19991115

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: UCB PHARMA, S.A., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UCB, S.A.;REEL/FRAME:021773/0126

Effective date: 20081010

Owner name: UCB PHARMA, S.A.,BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UCB, S.A.;REEL/FRAME:021773/0126

Effective date: 20081010

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12